{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:04:22Z","timestamp":1789664662694,"version":"4.0.1"},"reference-count":78,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.autrev.2011.05.001","type":"journal-article","created":{"date-parts":[[2011,5,22]],"date-time":"2011-05-22T17:12:23Z","timestamp":1306084343000},"page":"321-325","source":"Crossref","is-referenced-by-count":100,"title":["Therapeutic blockade of TNF in patients with SLE\u2014Promising or crazy?"],"prefix":"10.1016","volume":"11","author":[{"given":"Martin","family":"Aringer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S.","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2011.05.001_bb0005","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0016-5085(95)90277-5","article-title":"Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)","volume":"109","author":"van Dullemen","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2011.05.001_bb0010","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis [see comments]","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.05.001_bb0015","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E","article-title":"Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab","volume":"43","author":"Brandt","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.05.001_bb0020","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2011.05.001_bb0025","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.10671","article-title":"Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation","volume":"47","author":"Antoni","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.05.001_bb0030","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/rheumatology\/41.11.1303","article-title":"Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis","volume":"41","author":"Lamprecht","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2011.05.001_bb0035","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/rheumatology\/keg070","volume":"42","author":"Drewe","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2011.05.001_bb0040","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/ard.2003.015743","article-title":"Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor alpha as a new therapeutic option","volume":"63","author":"Tausche","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.05.001_bb0045","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 3","key":"10.1016\/j.autrev.2011.05.001_bb0050","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1136\/ard.2008.100834","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008","volume":"67","author":"Furst","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.05.001_bb0055","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2011.05.001_bb0060","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/art.10583","article-title":"Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept","volume":"46","author":"Lee","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.05.001_bb0065","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/art.10758","article-title":"Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents","volume":"48","author":"Slifman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.05.001_bb0070","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1172\/JCI750","article-title":"Theofilopoulos AN Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice","volume":"101","author":"Balomenos","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2011.05.001_bb0075","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1126\/science.279.5353.1052","article-title":"Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis","volume":"279","author":"Clynes","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.autrev.2011.05.001_bb0080","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.4049\/jimmunol.141.4.1197","article-title":"Fc-receptor cross-linking induces rapid secretion of tumor necrosis factor (cachectin) by human peripheral blood monocytes","volume":"141","author":"Debets","year":"1988","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2011.05.001_bb0085","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/BF00191429","article-title":"Cellular localization of inflammatory cytokines in human glomerulonephritis","volume":"424","author":"Takemura","year":"1994","journal-title":"Virchows Arch"},{"key":"10.1016\/j.autrev.2011.05.001_bb0090","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0046-8177(95)90253-8","article-title":"Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients","volume":"26","author":"Malide","year":"1995","journal-title":"Hum Pathol"},{"key":"10.1016\/j.autrev.2011.05.001_bb0095","first-page":"1444","article-title":"Tumor necrosis factor-alpha is expressed by glomerular visceral epithelial cells in human membranous nephropathy","volume":"146","author":"Neale","year":"1995","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2011.05.001_bb0100","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1191\/096120398678919949","article-title":"Renal expression of IL-6 and TNFalpha genes in lupus nephritis","volume":"7","author":"Herrera-Esparza","year":"1998","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2011.05.001_bb0105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1191\/0961203305lu2053oa","article-title":"Cytokine expression in lupus kidneys","volume":"14","author":"Aringer","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2011.05.001_bb0110","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.2005.039362","article-title":"Tumour necrosis factor alpha is expressed in refractory skin lesions from patients with subacute cutaneous lupus erythematosus","volume":"65","author":"Zampieri","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.05.001_bb0115","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/rheumatology\/35.11.1067","article-title":"Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus","volume":"35","author":"Studnicka-Benke","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.autrev.2011.05.001_bb0120","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/rheumatology\/40.8.876","article-title":"Serum interleukin-15 is elevated in systemic lupus erythematosus","volume":"40","author":"Aringer","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2011.05.001_bb0125","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/anr.1780320206","article-title":"Tumor necrosis factor in the serum of patients with systemic lupus erythematosus","volume":"32","author":"Maury","year":"1989","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.05.001_bb0130","first-page":"303","article-title":"Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity","volume":"24","author":"Gabay","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2011.05.001_bb0135","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1191\/0961203302lu160oa","article-title":"Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death","volume":"11","author":"Aringer","year":"2002","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2011.05.001_bb0140","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.4049\/jimmunol.141.9.3050","article-title":"Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis","volume":"141","author":"Boswell","year":"1988","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2011.05.001_bb0145","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/ki.1995.14","article-title":"Biphasic increase in circulating and renal TNF-alpha in MRL-lpr mice with differing regulatory mechanisms","volume":"47","author":"Yokoyama","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2011.05.001_bb0150","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.4049\/jimmunol.143.11.3470","article-title":"Tumor necrosis factor and IL-1 in New Zealand Black\/White mice. Enhanced gene expression and acceleration of renal injury","volume":"143","author":"Brennan","year":"1989","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2011.05.001_bb0155","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1365-2249.1991.tb05737.x","article-title":"Tumour necrosis factor\/cachectin plays a key role in autoimmune pulmonary inflammation in lupus-prone mice","volume":"85","author":"Deguchi","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2011.05.001_bb0160","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.4049\/jimmunol.157.4.1758","article-title":"Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr\/lpr mice by a transcriptional inhibitor of TNF-alpha","volume":"157","author":"Edwards","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2011.05.001_bb0165","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/1529-0131(199801)41:1<139::AID-ART17>3.0.CO;2-T","article-title":"Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor","volume":"41","author":"Su","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.05.001_bb0170","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1191\/096120301675275538","article-title":"Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFalpha monoclonal antibody and by pentoxiphylline","volume":"10","author":"Segal","year":"2001","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2011.05.001_bb0175","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/331356a0","article-title":"Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis","volume":"331","author":"Jacob","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2011.05.001_bb0180","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0090-1229(89)90157-8","article-title":"Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB\/NZW F1 mice","volume":"52","author":"Gordon","year":"1989","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.autrev.2011.05.001_bb0185","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1002\/1521-4141(200007)30:7<2038::AID-IMMU2038>3.0.CO;2-K","article-title":"Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor","volume":"30","author":"Kontoyiannis","year":"2000","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2011.05.001_bb0190","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/ar2341","article-title":"The role of tumor necrosis factor-alpha in systemic lupus erythematosus","volume":"10","author":"Aringer","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2011.05.001_bb0195","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","article-title":"Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials","volume":"43","author":"Charles","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.05.001_bb0200","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/art.21190","article-title":"Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis","volume":"52","author":"De Rycke","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.05.001_bb0205","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s10067-002-0654-5","article-title":"Anti-TNF-alpha-induced systemic lupus syndrome","volume":"22","author":"De Bandt","year":"2003","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2011.05.001_bb0210","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases","volume":"86","author":"Ramos-Casals","year":"2007","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2011.05.001_bb0215","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0016-5085(03)00701-7","article-title":"Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study","volume":"125","author":"Vermeire","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2011.05.001_bb0220","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2011.05.001_bb0225","doi-asserted-by":"crossref","first-page":"R545","DOI":"10.1186\/ar1715","article-title":"Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey","volume":"7","author":"De Bandt","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2011.05.001_bb0230","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/art.11033","article-title":"Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis","volume":"48","author":"Carlson","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.05.001_bb0235","first-page":"740","article-title":"Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept","volume":"32","author":"Mor","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2011.05.001_bb0240","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/ndt\/gfh832","article-title":"Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis","volume":"20","author":"Stokes","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2011.05.001_bb0245","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/0961203308100560","article-title":"Etanercept-associated SLE with lupus nephritis","volume":"18","author":"Neradova","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2011.05.001_bb0250","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/rheumatology\/41.10.1109","article-title":"Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: results of an open trial","volume":"41","author":"Ferraccioli","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2011.05.001_bb0255","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1073\/pnas.93.4.1624","article-title":"Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus","volume":"93","author":"Casciola-Rosen","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2011.05.001_bb0260","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1084\/jem.185.5.843","article-title":"Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus","volume":"185","author":"Utz","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2011.05.001_bb0265","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO;2-H","article-title":"Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus","volume":"41","author":"Herrmann","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.05.001_bb0270","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/art.22327","article-title":"Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus","volume":"56","author":"Aringer","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.05.001_bb0275","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1172\/JCI117394","article-title":"Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor\/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis","volume":"94","author":"Cope","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2011.05.001_bb0280","doi-asserted-by":"crossref","first-page":"5495","DOI":"10.4049\/jimmunol.166.9.5495","article-title":"Prolonged exposure of T cells to TNF down-regulates TCR zeta and expression of the TCR\/CD3 complex at the cell surface","volume":"166","author":"Isomaki","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2011.05.001_bb0285","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.4049\/jimmunol.167.12.6821","article-title":"In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL","volume":"167","author":"Via","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2011.05.001_bb0290","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1073\/pnas.0408506102","article-title":"Cross-regulation of TNF and IFN-alpha in autoimmune diseases","volume":"102","author":"Palucka","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2011.05.001_bb0295","first-page":"1559","article-title":"Influence of functional interleukin 10\/tumor necrosis factor-alpha polymorphisms on interferon-alpha, IL-10, and regulatory T cell population in patients with systemic lupus erythematosus receiving antimalarial treatment","volume":"35","author":"Lopez","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2011.05.001_bb0300","first-page":"1473","article-title":"A bridge between interferon-alpha and tumor necrosis factor in lupus","volume":"35","author":"Aringer","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2011.05.001_bb0305","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1002\/art.20576","article-title":"Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study","volume":"50","author":"Aringer","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.05.001_bb0310","unstructured":"Aringer M, Houssiau F, Gordon C, et al. Adverse events and efficacy of TNF\u00e1 blockade with infliximab in patients with systemic lupus erythematosus (SLE). Long-term follow-up of thirteen patients. Rheumatology. (Oxford)."},{"key":"10.1016\/j.autrev.2011.05.001_bb0315","first-page":"416","article-title":"Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: a prospective series of nine patients","volume":"27","author":"Matsumura","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2011.05.001_bb0320","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/0961203309102557","article-title":"Efficacy and safety of infliximab in active SLE: a pilot study","volume":"18","author":"Uppal","year":"2009","journal-title":"Lupus"},{"issue":"Supplement 9","key":"10.1016\/j.autrev.2011.05.001_bb0325","first-page":"S379","article-title":"Frequent infusion reactions associated with infliximab treatment in patients with polyarthritis related to systemic lupus erythematosus","volume":"48","author":"Katz","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"Supplement II","key":"10.1016\/j.autrev.2011.05.001_bb0330","article-title":"Long term safety and efficacy of open-label infliximab for SLE","volume":"455","author":"Aringer","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.05.001_bb0335","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1081\/IPH-120037721","article-title":"Lupus nephritis improvement after anti-tumor necrosis factor alpha monoclonal antibody (infliximab) treatment for Crohn's disease: a case report","volume":"26","author":"Principi","year":"2004","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.autrev.2011.05.001_bb0340","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1177\/0961203306070970","article-title":"Efficacy and safety of Etanercept, high-dose intravenous gammaglobulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancy","volume":"15","author":"Micheloud","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2011.05.001_bb0345","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s10067-006-0219-0","article-title":"Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis","volume":"26","author":"Hayat","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2011.05.001_bb0350","first-page":"S412","article-title":"Anti-TNF agents are effective and safe in the management of systemic lupus erythematosus","volume":"50","author":"Gonzalez","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.05.001_bb0355","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s10165-006-0561-8","article-title":"Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus","volume":"17","author":"Hayat","year":"2007","journal-title":"Mod Rheumatol"},{"issue":"Supplement 1","key":"10.1016\/j.autrev.2011.05.001_bb0360","first-page":"437","article-title":"Successful treatment of severe lupus arthritis with infliximab (Remicade)","volume":"62","author":"Fiehn","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.05.001_bb0365","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s10165-007-0006-z","article-title":"Successful use of etanercept in the treatment of acute lupus hemophagocytic syndrome","volume":"18","author":"Takahashi","year":"2008","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2011.05.001_bb0370","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ajh.20462","article-title":"Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis","volume":"81","author":"Henzan","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1016\/j.autrev.2011.05.001_bb0375","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/rheumatology\/kem205","article-title":"Successful treatment of refractory lupus-associated haemophagocytic lymphohistiocytosis with infliximab","volume":"46","author":"Ideguchi","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2011.05.001_bb0380","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1016\/j.jaad.2005.11.1090","article-title":"Case reports of etanercept in inflammatory dermatoses","volume":"54","author":"Norman","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.autrev.2011.05.001_bb0385","first-page":"S413","article-title":"Successful treatment of a patient suffering from a refractory subacute cutaneous lupus erthematosus (SCLE) with blockers of tumour necrosis factor a","volume":"50","author":"Hiepe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.05.001_bb0390","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10227-002-0134-1","article-title":"Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses","volume":"7","author":"Drosou","year":"2003","journal-title":"J Cutan Med Surg"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997211001030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997211001030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T23:32:56Z","timestamp":1686094376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997211001030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":78,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S1568997211001030"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2011.05.001","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}